The U.S. companion animal osteoarthritis market size was estimated at USD 776.97 million in 2024 and is projected to reach USD 4.19 billion by 2033, growing at a CAGR of 22.55% from 2025 to 2033. Key factors expected to drive the market include the rising prevalence of osteoarthritis, increasing R&D initiative, emerging novel treatments, and increasing awareness campaigns.
The U.S. companion animal osteoarthritis (CA OA) market is undergoing robust growth, fueled by innovation,
increased clinical awareness, and broader access to diverse treatment options. A convergence of advanced therapies,
preventive care initiatives, and owner-driven demand is reshaping how OA is managed in pets, particularly dogs. One of the most promising developments is the advancement of gene therapy, exemplified by CureLab Veterinary’s
ElenaVet, which demonstrated a remarkable 90% success rate in reducing pain and improving mobility in dogs with OA. This breakthrough highlights a shift toward disease-modifying approaches that offer longer-term benefits compared to conventional pain management therapies.
At the same time, veterinary-led awareness campaigns-as reported by DVM360-are raising the standard of care by emphasizing early detection, mobility screening, and proactive OA management. This growing clinical emphasis has led to better-informed pet owners and more timely treatment initiation, expanding the overall addressable market.
Complementing these efforts is the increasing availability of nutritional supplements specifically formulated for canine OA. The recent U.S. launch of a new supplement (DVM360) provides a non-prescription option for managing early-stage or adjunctive care, especially for cost-conscious pet owners or those seeking holistic solutions.
In parallel, regenerative therapies, such as stem cell treatments, are gaining momentum in specialty practices and progressive clinics. As outlined by Fitzpatrick Referrals, these therapies offer minimally invasive solutions that focus on joint restoration rather than symptom suppression-aligning with rising expectations for long-lasting, restorative care.
Further strengthening the market is a growing pipeline of oral therapeutics, including Can-Fite and Vetbiolix’s Piclidenoson, currently in advanced clinical development. This A3 adenosine receptor agonist is positioned to offer a convenient, non-invasive treatment option with global peak sales projected to exceed $445 million by 2034. Its progress reflects strong investor and clinical confidence in oral OA therapies as viable alternatives to injectables and NSAIDs.
In conclusion, the U.S. CA OA market is being driven by a comprehensive, multi-modal evolution-from cutting-edge gene and cell therapies to increased practitioner education and owner engagement. This diversified ecosystem improves patient outcomes and solidifies the U.S. as a global front-runner in advancing osteoarthritis care for companion animals.
This product will be delivered within 2 business days.
The U.S. companion animal osteoarthritis (CA OA) market is undergoing robust growth, fueled by innovation,
increased clinical awareness, and broader access to diverse treatment options. A convergence of advanced therapies,
preventive care initiatives, and owner-driven demand is reshaping how OA is managed in pets, particularly dogs. One of the most promising developments is the advancement of gene therapy, exemplified by CureLab Veterinary’s
ElenaVet, which demonstrated a remarkable 90% success rate in reducing pain and improving mobility in dogs with OA. This breakthrough highlights a shift toward disease-modifying approaches that offer longer-term benefits compared to conventional pain management therapies.
At the same time, veterinary-led awareness campaigns-as reported by DVM360-are raising the standard of care by emphasizing early detection, mobility screening, and proactive OA management. This growing clinical emphasis has led to better-informed pet owners and more timely treatment initiation, expanding the overall addressable market.
Complementing these efforts is the increasing availability of nutritional supplements specifically formulated for canine OA. The recent U.S. launch of a new supplement (DVM360) provides a non-prescription option for managing early-stage or adjunctive care, especially for cost-conscious pet owners or those seeking holistic solutions.
In parallel, regenerative therapies, such as stem cell treatments, are gaining momentum in specialty practices and progressive clinics. As outlined by Fitzpatrick Referrals, these therapies offer minimally invasive solutions that focus on joint restoration rather than symptom suppression-aligning with rising expectations for long-lasting, restorative care.
Further strengthening the market is a growing pipeline of oral therapeutics, including Can-Fite and Vetbiolix’s Piclidenoson, currently in advanced clinical development. This A3 adenosine receptor agonist is positioned to offer a convenient, non-invasive treatment option with global peak sales projected to exceed $445 million by 2034. Its progress reflects strong investor and clinical confidence in oral OA therapies as viable alternatives to injectables and NSAIDs.
In conclusion, the U.S. CA OA market is being driven by a comprehensive, multi-modal evolution-from cutting-edge gene and cell therapies to increased practitioner education and owner engagement. This diversified ecosystem improves patient outcomes and solidifies the U.S. as a global front-runner in advancing osteoarthritis care for companion animals.
U.S. Companion Animal Osteoarthritis Market Report Segmentation
This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. companion animal osteoarthritis market report based on product, animal, route of administration, and end use:Product Outlook (Revenue, USD Million, 2021 - 2033)
- Biologics
- Stem Cells
- Platelet-Rich Plasma (PRP)
- Monoclonal Antibodies (mAb)
- Other Biologics
- Viscosupplements
- Pharmaceuticals
- Steroids
- NSAIDS
- Others
- Nutritional Supplements
Animal Outlook (Revenue, USD Million, 2021 - 2033)
- Canine
- Equine
- Feline
Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
- Oral
- Injectable
- Intra-muscular
- Intra-articular
- Other Injectable
- Topical
End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Veterinary Hospitals/Clinics
- E-commerce
- Others
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Companion Animal Osteoarthritis Market Variable Trends & Scope
Chapter 4. U.S. Companion Animal Osteoarthritis Market: Product Estimates & Trend Analysis
Chapter 5. U.S. Companion Animal Osteoarthritis Market: Animal Estimates & Trend Analysis
Chapter 6. U.S. Companion Animal Osteoarthritis Market: By Route of Administration Estimates & Trend Analysis
Chapter 7. U.S. Companion Animal Osteoarthritis Market: By End Use Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Zoetis Inc.
- Boehringer Ingelheim
- Elanco Animal Health
- American Regent, Inc.
- Merck Animal Health (Merck & Co. Inc)
- Vetoquinol S.A.
- Ceva Sante Animale
- Virbac
- Biogenesis Bago
- Ardent Animal Health, LLC
- PetVivo Holdings, Inc. (Spryng)
- VetStem, Inc.
- Enso Discoveries
- Contura Vet US
- T-Cyte Therapeutics
- MEDREGO LLC
